US3894920A
(en)
|
1971-12-21 |
1975-07-15 |
Sagami Chem Res |
Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives
|
US4016287A
(en)
|
1972-07-17 |
1977-04-05 |
Boehringer Ingelheim Gmbh |
Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof
|
JPH03502535A
(ja)
|
1988-07-25 |
1991-06-13 |
フセソユズニ クルガンスキ ナウチニ ツェントル“ボススタノビテルナヤ トラフマトロギア イ オルトペディア” |
手の形成的復元のための伸延装置
|
TW219933B
(es)
|
1990-02-26 |
1994-02-01 |
Lilly Co Eli |
|
US5405613A
(en)
|
1991-12-11 |
1995-04-11 |
Creative Nutrition Canada Corp. |
Vitamin/mineral composition
|
TW352384B
(en)
|
1992-03-24 |
1999-02-11 |
Hoechst Ag |
Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
|
DE4219158A1
(de)
|
1992-06-11 |
1993-12-16 |
Thomae Gmbh Dr K |
Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
|
DE59401924D1
(de)
|
1993-11-02 |
1997-04-10 |
Hoechst Ag |
Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
|
EP0650960B1
(de)
|
1993-11-02 |
1997-03-05 |
Hoechst Aktiengesellschaft |
Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
|
NZ270267A
(en)
|
1993-12-30 |
1997-03-24 |
Hoechst Ag |
3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions
|
DE4410480A1
(de)
|
1994-03-25 |
1995-09-28 |
Hoechst Ag |
Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
DE4410423A1
(de)
|
1994-03-25 |
1995-09-28 |
Hoechst Ag |
Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
IL135495A
(en)
|
1995-09-28 |
2002-12-01 |
Hoechst Ag |
Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
|
JPH09221476A
(ja)
|
1995-12-15 |
1997-08-26 |
Otsuka Pharmaceut Co Ltd |
医薬組成物
|
JP2000509047A
(ja)
|
1996-04-30 |
2000-07-18 |
ヘキスト・アクチエンゲゼルシヤフト |
3―アルコキシピリジン―2―カルボキサミドエステル類、その製法および薬剤としてのその使用
|
DE19620041A1
(de)
|
1996-05-17 |
1998-01-29 |
Merck Patent Gmbh |
Adhäsionsrezeptor-Antagonisten
|
DE19650215A1
(de)
|
1996-12-04 |
1998-06-10 |
Hoechst Ag |
3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
|
US6420427B1
(en)
|
1997-10-09 |
2002-07-16 |
Ono Pharmaceutical Co., Ltd. |
Aminobutyric acid derivatives
|
DE19746287A1
(de)
|
1997-10-20 |
1999-04-22 |
Hoechst Marion Roussel De Gmbh |
Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
|
CA2325471C
(en)
|
1998-03-23 |
2010-08-17 |
Aventis Pharmaceuticals Products Inc. |
Piperididinyl and n-amidinopiperidinyl derivatives
|
US6281381B1
(en)
|
1998-08-27 |
2001-08-28 |
Teva Pharmaceutical Industries Ltd. |
Hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
|
ES2255320T3
(es)
|
1998-11-27 |
2006-06-16 |
Teva Pharmaceutical Industries Ltd. |
Forma v clorhidrato de sertralina.
|
US6500987B1
(en)
|
1998-11-27 |
2002-12-31 |
Teva Pharmaceutical Industries Ltd. |
Sertraline hydrochloride polymorphs
|
US6159379A
(en)
|
1999-05-04 |
2000-12-12 |
Baker Hughes Incorporated |
Organic ammonium salts for the removal of water soluble organics in produced water
|
JP2001048786A
(ja)
|
1999-08-05 |
2001-02-20 |
Yamanouchi Pharmaceut Co Ltd |
三環式ヘテロアリール誘導体
|
CZ2002404A3
(cs)
|
1999-08-11 |
2002-06-12 |
Teva Pharmaceutical Industries Ltd. |
Polymorfní formy torsemidu
|
YU35802A
(sh)
|
1999-11-17 |
2005-07-19 |
Teva Pharmaceutical Industries Ltd. |
Polimorfni oblik atorvastatin kalcijuma
|
KR20020062340A
(ko)
|
1999-12-14 |
2002-07-25 |
비오갈 기오기스제르갸르 알티. |
신규 형태의 프라바스타틴 나트륨
|
CN1411373A
(zh)
|
1999-12-16 |
2003-04-16 |
特瓦制药工业有限公司 |
制备来氟米特的新方法和新晶形的来氟米特
|
WO2001044262A1
(en)
|
1999-12-16 |
2001-06-21 |
Teva Pharmaceutical Industries Ltd. |
Processes for preparing clarithromycin polymorphs and novel polymorph iv
|
JP4057295B2
(ja)
|
1999-12-21 |
2008-03-05 |
テバ ファーマシューティカル インダストリーズ リミティド |
新規塩酸セルトラリン多形体、それらを調製するための方法、それらを含有する組成物およびそれらを用いる方法
|
JP2003519698A
(ja)
|
2000-01-07 |
2003-06-24 |
トランスフォーム ファーマスーティカルズ,インコーポレイテッド |
多様な固体形態のハイスループットでの形成、同定および分析
|
CA2397092A1
(en)
|
2000-01-11 |
2001-07-19 |
Teva Pharmaceutical Industries Ltd. |
Processes for preparing clarithromycin polymorphs
|
US6589758B1
(en)
|
2000-05-19 |
2003-07-08 |
Amgen Inc. |
Crystal of a kinase-ligand complex and methods of use
|
PT1309547E
(pt)
|
2000-07-27 |
2007-03-30 |
Teva Pharma |
Modafinil cristalino e puro, e processo para a sua preparação
|
US20020183553A1
(en)
|
2000-10-19 |
2002-12-05 |
Ben-Zion Dolitzky |
Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
|
YU30203A
(sh)
|
2000-10-19 |
2006-08-17 |
Teva Pharmaceutical Industries Ltd. |
Kristalna venlafaksin baza i novi polimorfi venlafaksin hidrohlorida, postupci za njegovo pripremanje
|
ES2204358T1
(es)
|
2000-10-30 |
2004-05-01 |
Teva Pharmaceutical Industries Ltd. |
Nuevas formas de cristal y de disolvente de hidrocloruro de ondasetron y procedimientos para su preparacion.
|
CA2426632C
(en)
|
2000-11-03 |
2008-08-05 |
Teva Pharmaceutical Industries, Ltd. |
Atorvastatin hemi-calcium form vii
|
IL156055A0
(en)
|
2000-11-30 |
2003-12-23 |
Teva Pharma |
Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
|
US7501450B2
(en)
|
2000-11-30 |
2009-03-10 |
Teva Pharaceutical Industries Ltd. |
Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
|
AU2002250057A1
(en)
|
2001-02-12 |
2002-08-28 |
Teva Pharmaceutical Industries Ltd. |
New crystal forms of oxcarbazepine and processes for their preparation
|
US6855510B2
(en)
|
2001-03-20 |
2005-02-15 |
Dana Farber Cancer Institute, Inc. |
Pharmaceuticals and methods for treating hypoxia and screening methods therefor
|
US6849718B2
(en)
|
2001-03-20 |
2005-02-01 |
Dana Farber Cancer Institute, Inc. |
Muteins of hypoxia inducible factor alpha and methods of use thereof
|
US20040146964A1
(en)
|
2001-03-21 |
2004-07-29 |
Maxwell Patrick Henry |
Assays, methods and means
|
EP1392303A4
(en)
|
2001-04-09 |
2005-01-26 |
Teva Pharma |
FEXOFENADINE HYDROCHLORIDE POLYMORPHS
|
SE0101327D0
(sv)
|
2001-04-12 |
2001-04-12 |
Astrazeneca Ab |
New crystalline forms
|
CA2453751A1
(en)
|
2001-08-01 |
2003-02-13 |
Biogal Gyogyszergyar Rt. |
Purification and crystalline forms of zapelon
|
IL160721A0
(en)
|
2001-09-07 |
2004-08-31 |
Teva Pharma |
Crystalline forms of valacyclovir hydrochloride
|
PT1451194E
(pt)
|
2001-10-03 |
2007-01-31 |
Teva Pharma |
Preparação de hemi-hidrato de levofloxacina
|
US6566088B1
(en)
|
2001-10-04 |
2003-05-20 |
Board Of Regents, The University Of Texas System |
Prolyl-4-hydroxylases
|
GB0124941D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
EP1453509A2
(en)
|
2001-11-08 |
2004-09-08 |
Teva Pharmaceutical Industries Ltd. |
Polymorphs of fexofenadine base
|
CA2465597A1
(en)
|
2001-11-14 |
2003-06-12 |
Ben Zion Dolitzky |
Amorphous and crystalline forms of losartan potassium and process for their preparation
|
AU2002362061A1
(en)
|
2001-12-04 |
2003-06-17 |
Biogal Gyogyszergyar Rt |
Preparation of orlistat and orlistat crystalline forms
|
CN100522946C
(zh)
|
2001-12-06 |
2009-08-05 |
法布罗根股份有限公司 |
低氧诱导因子(HIF)α的稳定化
|
EP1467735B1
(en)
|
2001-12-18 |
2008-12-10 |
Teva Pharmaceutical Industries Ltd. |
Polymorphs of clopidogrel hydrogensulfate
|
HUP0600679A2
(en)
|
2001-12-28 |
2008-06-30 |
Biogal Gyogyszergyar |
Processes for preparing crystalline and amorphous mupirocin calcium and pharmaceutical compositions containing the same
|
EP1474133A4
(en)
|
2002-01-15 |
2006-02-01 |
Teva Pharma |
SOLID CRYSTALLINE CARVEDILOL BODIES AND METHODS OF MAKING SAME
|
DE03713610T1
(de)
|
2002-02-15 |
2005-10-20 |
Teva Pharma |
Neue kristallformen von atorvastatin-hemicalcium und verfahren zu deren herstellung, sowie neue verfahren zur herstellung der formen i, viii und ix von atorvastatin-hemicalcium
|
US20030216376A1
(en)
|
2002-03-20 |
2003-11-20 |
Revital Lifshitz-Liron |
Crystalline forms of quetiapine hemifumarate
|
KR20040093187A
(ko)
|
2002-03-27 |
2004-11-04 |
테바 파마슈티컬 인더스트리즈 리미티드 |
란소프라졸 다형 및 그것의 제조 방법
|
AU2003209167A1
(en)
|
2002-04-11 |
2003-10-27 |
Teva Pharmaceutical Industries Ltd |
Novel polymorphs and pseudopolymorphs of risedronate sodium
|
CA2483569A1
(en)
|
2002-04-29 |
2003-11-13 |
Tamar Nidam |
Process for preparation of polymorphic form ii of sertraline hydrochloride, pharmaceutical formulations and methods of administration thereof
|
AU2003223763A1
(en)
|
2002-04-30 |
2003-11-17 |
Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag |
Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical compositions containing the novel forms and methods for treating nausea using them
|
CN1665504A
(zh)
|
2002-05-10 |
2005-09-07 |
特瓦制药工业有限公司 |
新晶型的加替沙星
|
JP2005532356A
(ja)
|
2002-06-10 |
2005-10-27 |
テバ ファーマシューティカル インダストリーズ リミティド |
塩酸フェキソフェナジンの多型体xvi
|
JP2005532364A
(ja)
|
2002-06-14 |
2005-10-27 |
テバ ファーマシューティカル インダストリーズ リミティド |
ガチフロキサシンの新規結晶質形態
|
IL166308A0
(en)
|
2002-07-18 |
2006-01-15 |
|
Polymorphic forms of nateglinide
|
US7534913B2
(en)
|
2002-07-18 |
2009-05-19 |
Teva Pharmaceutica Industries Ltd. |
Crystalline form of nateglinide
|
US20040022764A1
(en)
*
|
2002-07-31 |
2004-02-05 |
Hanan Polansky |
Inhibition of microcompetition with a foreign polynucleotide as treatment of chronic disease
|
EP1545530A1
(en)
|
2002-08-06 |
2005-06-29 |
Teva Pharmaceutical Industries Limited |
Novel crystalline forms of gatifloxacin
|
US20040097528A1
(en)
|
2002-08-26 |
2004-05-20 |
Ben-Zion Dolitzky |
Crystalline solid famciclovir forms I, II, III and preparation thereof
|
US20050043329A1
(en)
|
2002-09-06 |
2005-02-24 |
Shlomit Wizel |
Crystalline forms of valacyclovir hydrochloride
|
AU2003297594A1
(en)
|
2002-11-28 |
2004-06-23 |
Teva Pharmaceutical Industries Ltd. |
Crystalline form f of atorvastatin hemi-calcium salt
|
US7618940B2
(en)
|
2002-12-06 |
2009-11-17 |
Fibrogen, Inc. |
Fat regulation
|
US8124582B2
(en)
|
2002-12-06 |
2012-02-28 |
Fibrogen, Inc. |
Treatment of diabetes
|
JP2006511618A
(ja)
|
2002-12-12 |
2006-04-06 |
テバ ファーマシューティカル インダストリーズ リミティド |
ガチフロキサシンの結晶形態および調製の方法
|
US7323459B2
(en)
|
2002-12-24 |
2008-01-29 |
Teva Pharmaceutical Industries Ltd. |
Crystal forms, methods for their preparation and method for preparation of olanzapine
|
WO2004108700A1
(en)
|
2003-03-12 |
2004-12-16 |
Teva Gyogyszergyar Reszvenytarsasag |
Processes for preparation of polymorphic forms of desloratadine
|
ES2245277T1
(es)
|
2003-03-12 |
2006-01-01 |
Teva Pharmaceutical Industries Limited |
Solidos cristalinos y amorfos de pantoprazol y procedimientos para su preparacion.
|
US20040242661A1
(en)
|
2003-03-17 |
2004-12-02 |
Igor Rukhman |
Polymorphs of valsartan
|
CN1802371A
(zh)
|
2003-05-15 |
2006-07-12 |
特瓦药厂有限公司 |
残余溶剂含量极低的阿兹托南β多晶型
|
EP2014660A3
(en)
|
2003-06-02 |
2009-07-15 |
Teva Pharmaceutical Industries Ltd |
Novel crystalline forms of valacyclovir hydrochloride
|
KR20060015750A
(ko)
|
2003-06-03 |
2006-02-20 |
테바 파마슈티컬 인더스트리즈 리미티드 |
지프라시돈 HCl의 다형 형태 및 그 제조 방법
|
PT1644336E
(pt)
|
2003-06-06 |
2011-04-21 |
Fibrogen Inc |
Compostos de heteroarilo que contêm azoto e sua utilização no aumento da eritropoetina endógena
|
GB0314129D0
(en)
|
2003-06-18 |
2003-07-23 |
Astrazeneca Ab |
Therapeutic agents
|
US7368468B2
(en)
|
2003-06-18 |
2008-05-06 |
Teva Pharmaceutical Industries Ltd. |
Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them
|
KR20060024428A
(ko)
|
2003-06-18 |
2006-03-16 |
테바 파마슈티컬 인더스트리즈 리미티드 |
플루바스타틴 나트륨 결정 형태, 이것의 제조 방법, 상기결정 형태를 포함하는 조성물 및 상기 결정 형태를이용하는 방법
|
EP1612212A1
(en)
|
2003-07-03 |
2006-01-04 |
Teva Pharmaceutical Industries Ltd |
Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
|
CA2546701C
(en)
|
2003-11-24 |
2010-07-27 |
Teva Pharmaceutical Industries Ltd. |
Crystalline ammonium salts of rosuvastatin
|
PT1613598E
(pt)
|
2003-12-16 |
2012-01-13 |
Teva Pharma |
Métodos para preparar formas cristalinas de aripiprazol
|
CA2550886A1
(en)
|
2003-12-16 |
2005-06-30 |
Teva Pharmaceutical Industries Ltd. |
Polymorphic forms of tegaserod base and salts thereof
|
CA2550485A1
(en)
|
2003-12-18 |
2005-07-07 |
Teva Pharmaceutical Industries Ltd. |
Polymorphic form b2 of ziprasidone base
|
CA2554572A1
(en)
|
2004-01-30 |
2005-08-18 |
Teva Pharmaceutical Industries Ltd. |
Montelukast free acid polymorphs
|
CA2554789A1
(en)
|
2004-01-30 |
2005-08-18 |
Teva Pharmaceutical Industries, Ltd. |
Montelukast sodium polymorphs
|
EP1713795A2
(en)
|
2004-02-11 |
2006-10-25 |
Teva Pharmaceutical Industries Ltd. |
Candesartan cilexetil polymorphs
|
JPWO2005108370A1
(ja)
|
2004-04-16 |
2008-03-21 |
味の素株式会社 |
ベンゼン化合物
|
MXPA06012281A
(es)
|
2004-04-26 |
2007-07-18 |
Teva Pharma |
Formas cristalinas de clorhidrato de fexofenadina y procesos para su preparacion.
|
JP2007528858A
(ja)
|
2004-05-07 |
2007-10-18 |
テバ ファーマシューティカル インダストリーズ リミティド |
ナテグリニドの多形形態
|
TW200613304A
(en)
|
2004-05-18 |
2006-05-01 |
Teva Pharma |
Drying process for preparing crystalline solid famciclovir
|
US7488758B2
(en)
|
2004-05-20 |
2009-02-10 |
Teva Pharmaceutical Fine Chemicals, S.R.L. |
Levalbuterol hydrochloride polymorph B
|
MX2007000087A
(es)
|
2004-06-23 |
2007-11-06 |
Teva Pharma |
Acido ibandronico solido y cristalino.
|
WO2006004922A1
(en)
|
2004-06-29 |
2006-01-12 |
Teva Pharmaceutical Industries Ltd. |
Crystalline form iv of linezolid
|
US20060052350A1
(en)
|
2004-07-01 |
2006-03-09 |
Alexei Ploutno |
Crystalline forms of 1,24(S)-dihydroxy vitamin D2
|
DE602005020014D1
(de)
|
2004-07-20 |
2010-04-29 |
Teva Gyogyszergyar Zartkoeruen |
Kristallines mycophenolat-natrium
|
US7473804B2
(en)
|
2004-07-22 |
2009-01-06 |
Teva Pharmaceutical Fine Chemicals S.R.L. |
Polymorphs of atomoxetine hydrochloride
|
DE202005020766U1
(de)
|
2004-07-22 |
2006-10-05 |
Teva Pharmaceutical Industries Ltd. |
Neue Kristallformen von Atorvastatin-Hemi-Calcium
|
ATE495747T1
(de)
|
2004-08-23 |
2011-02-15 |
Teva Pharma |
Kristalline form des ibandronat-natriums und herstellungsverfahren dafür
|
EP1704152A2
(en)
|
2004-09-21 |
2006-09-27 |
Teva Pharmaceutical Industries Ltd |
Crystalline clopidogrel hydrobromide and processes for preparation thereof
|
WO2006037042A1
(en)
|
2004-09-28 |
2006-04-06 |
Teva Pharmaceutical Industries Ltd. |
Fexofenadine crystal form and processes for its preparation thereof
|
EP1799216A2
(en)
|
2004-11-02 |
2007-06-27 |
Teva Pharmaceutical Industries Ltd |
Tadalafil crystal forms and processes for preparing them
|
MX2007005348A
(es)
|
2004-11-03 |
2007-06-25 |
Teva Pharma |
Formas amorfas y polimorficas de sodio de telmisartan.
|
WO2006055964A2
(en)
|
2004-11-19 |
2006-05-26 |
Teva Pharmaceutical Industries Ltd. |
Zolmitriptan crystal forms
|
JP2007519758A
(ja)
|
2004-12-01 |
2007-07-19 |
テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ |
結晶マクロライドの生成方法
|
WO2006060808A1
(en)
|
2004-12-03 |
2006-06-08 |
Teva Pharmaceutical Industries Ltd. |
Ezetimibe polymorphs
|
MX2007007302A
(es)
|
2005-01-11 |
2008-02-11 |
Teva Pharm Fine Chemicals Srl |
Proceso para la preparacion de clorhidrato de 1-amino-3,5-dimetiladamantano.
|
WO2006081515A2
(en)
|
2005-01-27 |
2006-08-03 |
Teva Pharmaceutical Industries Ltd. |
Duloxetine hydrochloride polymorphs
|
US20080213404A1
(en)
|
2005-02-04 |
2008-09-04 |
Johnson Randall S |
Hif Modulating Compounds and Methods of Use Thereof
|
CA2602073A1
(en)
|
2005-02-24 |
2006-08-31 |
Teva Pharmaceutical Industries Ltd. |
Processes for the preparation of linezolid intermediate
|
AU2006216695A1
(en)
|
2005-02-24 |
2006-08-31 |
Teva Pharmaceutical Industries, Ltd. |
Crystals of ladostigil tartrate, methods of production and pharmaceutical compositions thereof
|
WO2006096809A1
(en)
|
2005-03-08 |
2006-09-14 |
Teva Pharmaceutical Industries Ltd. |
Crystal forms of (s)-(+)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl) propanamine oxalate and the preparation thereof
|
WO2006098834A2
(en)
|
2005-03-14 |
2006-09-21 |
Teva Pharmaceutical Industries Ltd. |
Crystalline forms of ziprasidone mesylate
|
EP1866275A1
(en)
|
2005-04-06 |
2007-12-19 |
Teva Pharmaceutical Industries Ltd. |
Crystalline forms of pregabalin
|
DE102005019712A1
(de)
|
2005-04-28 |
2006-11-09 |
Bayer Healthcare Ag |
Dipyridyl-dihydropyrazolone und ihre Verwendung
|
CN102845804A
(zh)
|
2005-05-23 |
2013-01-02 |
卡夫食品环球品牌有限责任公司 |
口味增强剂组合物及包含该组合物的饮料
|
KR20070083471A
(ko)
|
2005-05-23 |
2007-08-24 |
테바 파마슈티컬 인더스트리즈 리미티드 |
시나칼셋 염산염 결정형 i의 제조 방법
|
EP1893186A2
(en)
|
2005-06-06 |
2008-03-05 |
Fibrogen, Inc. |
Improved treatment for anemia using a hif-alpha stabilising agent
|
US20070100165A1
(en)
|
2005-06-09 |
2007-05-03 |
Ronen Borochovitz |
Process for preparation of sertraline hydrochloride form I
|
KR20070088507A
(ko)
|
2005-06-09 |
2007-08-29 |
테바 파마슈티컬 인더스트리즈 리미티드 |
카베딜올의 결정질 형태 및 이것의 제조 방법
|
WO2006138511A2
(en)
|
2005-06-15 |
2006-12-28 |
Fibrogen, Inc. |
Use of hif 1alfa modulators for treatment of cancer
|
KR20070062504A
(ko)
|
2005-06-22 |
2007-06-15 |
테바 파마슈티컬 인더스트리즈 리미티드 |
테가세로드 말레이트의 다형태
|
WO2007033216A2
(en)
|
2005-09-12 |
2007-03-22 |
Beth Israel Deaconess Medical Center |
Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
|
WO2007038571A2
(en)
|
2005-09-26 |
2007-04-05 |
Smithkline Beecham Corporation |
Prolyl hydroxylase antagonists
|
US20070088082A1
(en)
|
2005-09-28 |
2007-04-19 |
Judith Aronhime |
Polymorphic forms of ladostigil tartrate
|
US20090176726A1
(en)
|
2005-10-11 |
2009-07-09 |
Fisher David E |
Methods for treating mitf-related disorders
|
NZ567088A
(en)
|
2005-10-19 |
2012-06-29 |
Teva Pharma |
Crystals of laquinimod sodium, and process for the manufacture thereof
|
WO2007053724A2
(en)
|
2005-10-31 |
2007-05-10 |
Teva Pharmaceutical Industries Ltd. |
Crystalline forms of cefdinir potassium salt
|
WO2007053722A2
(en)
|
2005-10-31 |
2007-05-10 |
Teva Pharmaceutical Industries Ltd. |
Crystalline form of cefdinir cesium salt
|
WO2007059307A2
(en)
|
2005-11-15 |
2007-05-24 |
Teva Pharmaceutical Industries Ltd. |
Crystalline and amorphous forms of telithromycin
|
JP2009516655A
(ja)
|
2005-11-22 |
2009-04-23 |
テバ ファーマシューティカル インダストリーズ リミティド |
シナカルセット塩酸塩の結晶形フォーム(Form)、およびそれらの調製方法
|
US7728130B2
(en)
|
2005-12-09 |
2010-06-01 |
Amgen Inc. |
Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity
|
KR20100023059A
(ko)
|
2005-12-13 |
2010-03-03 |
테바 파마슈티컬 인더스트리즈 리미티드 |
아토바스타틴 헤미칼슘의 결정형 및 이의 제조 방법
|
US20070203177A1
(en)
|
2006-01-05 |
2007-08-30 |
Janos Hajko |
Forms of dolasetron mesylate and processes for their preparation
|
EP1971618A2
(en)
|
2006-01-09 |
2008-09-24 |
Btg International Limited |
Modulators of hypoxia inducible factor-1 and related uses
|
WO2007082899A1
(en)
|
2006-01-17 |
2007-07-26 |
Vib Vzw |
Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
|
WO2007084761A1
(en)
|
2006-01-18 |
2007-07-26 |
Teva Pharmaceutical Industries Ltd. |
Maleate salt of tegaserod and crystalline forms thereof
|
WO2007084667A2
(en)
|
2006-01-19 |
2007-07-26 |
Osi Pharmaceutical, Inc. |
Fused heterobicyclic kinase inhibitors
|
JP4801451B2
(ja)
|
2006-01-19 |
2011-10-26 |
株式会社日立ハイテクノロジーズ |
走査電子顕微鏡等に用いる電子銃の制御装置及び制御方法
|
ITMI20060179A1
(it)
|
2006-02-02 |
2007-08-03 |
Abiogen Pharma Spa |
Procedimento per la risoluzione di miscele racemiche e complesso diastereoisomerico di un agente risolvente e di unantiomero di interesse
|
WO2007098273A2
(en)
|
2006-02-21 |
2007-08-30 |
Teva Pharmaceutical Industries Ltd. |
Novel crystalline forms of armodafinil and preparation thereof
|
MX2007013286A
(es)
|
2006-02-27 |
2008-03-07 |
Teva Pharma |
Formas novedosas de sodio de fluvastatina y preparacion de ellas.
|
US7588924B2
(en)
|
2006-03-07 |
2009-09-15 |
Procter & Gamble Company |
Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
|
TW200808793A
(en)
|
2006-03-07 |
2008-02-16 |
Smithkline Beecham Corp |
Prolyl hydroxylase inhibitors
|
US20080027223A1
(en)
|
2006-03-23 |
2008-01-31 |
Teva Pharmaceutical Industries Ltd. |
Polymorphs of eszopiclone malate
|
WO2007136990A2
(en)
|
2006-05-16 |
2007-11-29 |
Smithkline Beecham Corporation |
Prolyl hydroxylase inhibitors
|
PE20080209A1
(es)
|
2006-06-23 |
2008-05-15 |
Smithkline Beecham Corp |
Derivados de glicina como inhibidores de prolil hidroxilasa
|
EP4095127A1
(en)
*
|
2006-06-26 |
2022-11-30 |
Akebia Therapeutics Inc. |
Prolyl hydroxylase inhibitors and methods of use
|
CL2008000066A1
(es)
|
2007-01-12 |
2008-08-01 |
Smithkline Beecham Corp |
Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem
|
CL2008000065A1
(es)
|
2007-01-12 |
2008-09-22 |
Smithkline Beecham Corp |
Compuestos derivados de glicina n-sustituida, inhibidores de hif prolil hidroxilasas; su proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anemia.
|
US7569726B2
(en)
|
2007-04-18 |
2009-08-04 |
Amgen Inc. |
Indanone derivatives that inhibit prolyl hydroxylase
|
EP2136810A4
(en)
|
2007-04-18 |
2012-01-04 |
Merck Sharp & Dohme |
NOVEL 1,8-NAPHTHYRIDINE COMPOUNDS
|
ES2389063T3
(es)
|
2007-05-04 |
2012-10-22 |
Amgen, Inc |
Derivados de tienopiridina y tiazolopiridina que inhiben la actividad prolil hidroxilasa
|
CN101678011B
(zh)
|
2007-05-16 |
2012-07-18 |
默沙东公司 |
螺氮茚酮化合物
|
TW200908984A
(en)
|
2007-08-07 |
2009-03-01 |
Piramal Life Sciences Ltd |
Pyridyl derivatives, their preparation and use
|
US20110028507A1
(en)
|
2007-08-10 |
2011-02-03 |
Crystalgenomics, Inc. |
Pyridine derivatives and methods of use thereof
|
WO2009039323A1
(en)
|
2007-09-19 |
2009-03-26 |
Smithkline Beecham Corporation |
Prolyl hydroxylase inhibitors
|
WO2009039321A1
(en)
|
2007-09-19 |
2009-03-26 |
Smithkline Beecham Corporation |
Prolyl hydroxylase inhibitors
|
WO2009043093A1
(en)
|
2007-10-04 |
2009-04-09 |
Newsouth Innovations Pty Limited |
Hif inhibition
|
WO2009049112A1
(en)
|
2007-10-10 |
2009-04-16 |
Smithkline Beecham Corporation |
Prolyl hydroxylase inhibitors
|
MX2010005115A
(es)
|
2007-11-08 |
2010-05-27 |
Genentech Inc |
Anticuerpos anti-factor b y sus usos.
|
WO2009067790A1
(en)
|
2007-11-26 |
2009-06-04 |
Uti Limited Partnership |
STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION
|
AU2008329746A1
(en)
|
2007-11-30 |
2009-06-04 |
Glaxosmithkline Llc |
Prolyl hydroxylase inhibitors
|
JP2011508725A
(ja)
|
2007-11-30 |
2011-03-17 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
プロリルヒドロキシラーゼ阻害剤
|
EP2227475B1
(en)
|
2007-12-03 |
2014-02-19 |
Fibrogen, Inc. |
Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
|
WO2009086044A1
(en)
|
2007-12-19 |
2009-07-09 |
Smith Kline Beecham Corporation |
Prolyl hydroxylase inhibitors
|
WO2009086592A1
(en)
|
2008-01-04 |
2009-07-16 |
Garvan Institute Of Medical Research |
Method of increasing metabolism
|
EP2252619B1
(en)
|
2008-01-11 |
2013-10-09 |
Fibrogen, Inc. |
Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
|
AR071997A1
(es)
*
|
2008-06-04 |
2010-07-28 |
Bristol Myers Squibb Co |
Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
|
NO2686520T3
(es)
|
2011-06-06 |
2018-03-17 |
|
|
CN103717214A
(zh)
|
2011-06-06 |
2014-04-09 |
阿克比治疗有限公司 |
用于稳定低氧诱导因子-2α作为治疗癌症的方法的化合物和组合物
|
KR102029951B1
(ko)
*
|
2011-07-22 |
2019-11-08 |
베이징 베타 파머수티컬 컴퍼니 리미티드 |
프로릴 히드록실라제 억제제로서 화합물의 다형체형, 및 이의 용도
|
US8772895B2
(en)
|
2011-11-28 |
2014-07-08 |
Taiwan Semiconductor Manufacturing Company, Ltd. |
Dark current reduction for back side illuminated image sensor
|
EP2637274B1
(en)
|
2012-03-05 |
2022-05-04 |
Vetco Gray Scandinavia AS |
Power cable termination arrangement
|
BR112015031027A2
(pt)
|
2013-06-13 |
2017-08-29 |
Akebia Therapeutics Inc |
Uso de um composto, método in vitro, composição farmacêutica e forma de dosagem única
|
MX2021001169A
(es)
|
2013-11-15 |
2023-02-10 |
Akebia Therapeutics Inc |
Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acético, composiciones, y usos de las mismas.
|
WO2015112831A1
(en)
|
2014-01-23 |
2015-07-30 |
Akebia Therapeutics, Inc. |
Compositions and methods for treating ocular diseases
|
BR112017015852A2
(pt)
|
2015-01-23 |
2018-03-27 |
Akebia Therapeutics Inc |
forma de cristal, sal hemicálcico, sal hemicálcico di-hidratado, sal monossódico hidratado, sal bissódico monoidratado, sal monossódico anidro e método para preparar o composto 1
|
WO2016153996A1
(en)
|
2015-03-20 |
2016-09-29 |
Akebia Therapeutics, Inc. |
Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors
|
IL292262B2
(en)
|
2015-04-01 |
2024-02-01 |
Akebia Therapeutics Inc |
Formulation of an oral administration form of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid
|
EP3549932B1
(en)
|
2016-12-13 |
2020-09-30 |
Crystal Pharmaceutical (Suzhou) Co., Ltd. |
Novel crystalline forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid and processes for preparation thereof
|
MX2020011845A
(es)
|
2018-05-09 |
2021-01-15 |
Akebia Therapeutics Inc |
Proceso para preparar acido 2-[[5-(3-clorofenil)-3-hidroxipiridina -2-carbonil]amino]acetico.
|
AU2020374963A1
(en)
|
2019-10-31 |
2022-06-09 |
Akebia Therapeutics, Inc. |
Therapeutic methods using vadadustat
|
US11524939B2
(en)
|
2019-11-13 |
2022-12-13 |
Akebia Therapeutics, Inc. |
Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
|